Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)
Savara (SVRA) posted quarterly Net Income towards Common Stockholders of -$37.3 million for Q1 2026, down 39.96% year-over-year from -$62.1 million in Q1 2025, and down 15.66% quarter-over-quarter from -$32.2 million in Q4 2025.
Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$37.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million; the TTM figure through Mar 2026 stood at -$129.5 million (down 26.73% YoY), while the FY2025 annual figure was -$118.8 million, down 23.94% from the prior year.
- Net Income towards Common Stockholders retreated to -$37.3 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$8.3 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$20.3 million across 5 years, with a median of -$20.3 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders advanced 18.76% — and 2024, when it sank 94.38%.
- Savara's Net Income towards Common Stockholders stood at -$10.3 million in 2022, then tumbled by 56.3% to -$16.1 million in 2023, then slumped by 80.41% to -$29.0 million in 2024, then slipped by 10.99% to -$32.2 million in 2025, then decreased by 15.66% to -$37.3 million in 2026.
- Business Quant data shows SVRA's Net Income towards Common Stockholders at -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -40.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.23 Mn |
| Mar 31, 2026 | -37.28 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -30.40 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.04 Mn |
| Sep 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -22.24 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.10 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.39 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -10.55 Mn |